USD10
GLSI Shares
About Greenwich LifeSciencesGreenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
USD10
GLSI Shares
About Greenwich LifeSciencesGreenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
Stats
TRADING WINDOW
Closed
OPENS AT
Mar 27 at 1:30 PM GMT+0
MARKET CAP
$349.83M
OPEN PRICE
Not enough data
LOW (1Y)
$7.78
HIGH (1Y)
$34.10
LOW (24H)
$25.00
HIGH (24H)
$26.85
VOLUME (24H)
$394.00
99.69%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $25.49 | |
1 Week | $25.65 | |
1 Month | $27.16 | |
1 Year | $10.22 |